Biomarker proteasome levels predict response to combination therapy with carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma patients Meeting Abstract
| Authors: | Korde, N.; Dosani, T.; Simakova, O.; Mailankody, S.; Costello, R.; Roschewski, M.; Yuan, C.; Stetler-Stevenson, M.; Figg, W. D.; Landgren, O.; Maric, I. |
| Abstract Title: | Biomarker proteasome levels predict response to combination therapy with carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma patients |
| Meeting Title: | 56th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 124 |
| Issue: | 21 |
| Meeting Dates: | 2014 Dec 6-9 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2014-12-06 |
| Language: | English |
| ACCESSION: | WOS:000349243505190 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V124.21.2080.2080 |
| Notes: | Meeting Abstract: 2080 -- 56th Annual Meeting of the American-Society-of-Hematology -- DEC 06-09, 2014 -- San Francisco, CA -- Source: Wos |
Altmetric
Citation Impact
